Interpretation of the ALLHAT interim analysis and implications for the treatment of patients with BPH

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Urology

Background:

• The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) investigated cardiovascular disease incidence in hypertensive patients.
• Key drugs studied included doxazosin, amlodipine, lisinopril, and chlorthalidone.

Purpose of the Study:

• To compare the efficacy of doxazosin, amlodipine, and lisinopril against chlorthalidone in preventing cardiovascular disease.
• To interpret interim data from the ALLHAT trial regarding doxazosin's safety profile.
• To address concerns about alpha-1 adrenoceptor antagonists in managing benign prostatic hyperplasia (BPH).

Main Methods:

• An interim analysis of 24,335 high-risk hypertensive patients was conducted.
• The doxazosin treatment arm was discontinued due to safety concerns.
• Comparative analysis of cardiovascular endpoints between treatment groups.

Main Results:

• The doxazosin arm of the ALLHAT trial was stopped early.
• Doxazosin showed an increased incidence of secondary cardiovascular endpoints compared to chlorthalidone.
• This highlights potential risks associated with alpha-1 adrenoceptor antagonists.

Conclusions:

• The findings suggest caution when using doxazosin in hypertensive patients.
• The study provides insights into the interpretation of interim trial data.
• Clarification on the use of alpha-1 adrenoceptor antagonists in patients with hypertension and BPH is offered.